These robust, durable results in a difficult-to-treat population significantly de-risk the ongoing Phase 3 trial and support a potential best-in-class profile. Traders should monitor the upcoming investor call on April 22 for additional data clarity and management commentary on regulatory strategy. A positive Phase 3 readout could catalyze substantial upside.
Price Chart
Executive Summary
Kyverna Therapeutics announced positive longer-term follow-up data from the Phase 2 portion of its KYSA-6 trial of miv-cel in generalized myasthenia gravis (gMG), showing 100% of patients achieved rapid, sustained improvements across key clinical endpoints at 24 weeks with a well-tolerated safety profile. The data reinforce miv-cel’s potential as a best-in-class, single-dose therapy capable of delivering durable, drug-free remission.
Key Facts
- 100% of patients achieved clinically meaningful reductions in MG-ADL and QMG scores at 24 weeks
- Mean reductions: -8.5 points (MG-ADL) and -11.3 points (QMG) at Week 24
- Deep responses sustained out to 52 weeks in three patients
- 57% of patients achieved minimal symptom expression (MG-ADL 0 or 1) at last follow-up
- No high-grade cytokine release syndrome (CRS) or ICANS events observed
- Two transient grade 3/4 neutropenia events, consistent with lymphodepletion
Financial Impact
Non-dilutive, clinical-stage value inflection: data significantly de-risk Phase 3 trial and enhance commercial potential for miv-cel in gMG, a market with ~80,000 US patients
Risk Factors
- Phase 2 data are from a small sample (n=7) and not randomized
- Forward-looking statements are subject to regulatory, clinical, and commercial execution risks
- Phase 3 trial may not replicate Phase 2 results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276926 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.27 (−9.61%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.27 (−24.61%) |
Aug 11, 2026 10w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Aug 11, 2026 10w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.27 (−33.46%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.27 (−46.28%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.27 (+34.57%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.27 (−41.44%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.27 (−48.48%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.27 (−53.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers